Citizens Jmp Cuts Pharvaris (NASDAQ:PHVS) Price Target to $74.00

Pharvaris (NASDAQ:PHVS) had its target price trimmed by Citizens Jmp from $75.00 to $74.00 in a report published on Wednesday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Other research analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wedbush boosted their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. UBS Group set a $74.00 price target on Pharvaris in a research note on Wednesday. Finally, Royal Bank Of Canada dropped their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $49.18.

Pharvaris Trading Down 1.0%

NASDAQ PHVS opened at $30.40 on Wednesday. The business’s 50-day moving average price is $28.14 and its two-hundred day moving average price is $26.56. Pharvaris has a 12 month low of $15.46 and a 12 month high of $33.33. The firm has a market capitalization of $1.99 billion, a PE ratio of -9.56 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. As a group, analysts forecast that Pharvaris will post -3.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.32, for a total value of $881,402.40. Following the transaction, the director owned 355,167 shares in the company, valued at $10,768,663.44. This trade represents a 7.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Berndt Modig sold 23,333 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $27.74, for a total value of $647,257.42. Following the completion of the transaction, the chief executive officer owned 142,084 shares in the company, valued at $3,941,410.16. This represents a 14.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 150,659 shares of company stock worth $4,489,587 over the last three months. Company insiders own 11.84% of the company’s stock.

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL purchased a new stake in Pharvaris in the third quarter worth $1,943,000. Patient Square Capital LP increased its position in Pharvaris by 41.4% in the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after buying an additional 101,098 shares during the last quarter. JPMorgan Chase & Co. increased its position in Pharvaris by 710.4% in the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after buying an additional 23,743 shares during the last quarter. Boothbay Fund Management LLC increased its position in Pharvaris by 735.1% in the third quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after buying an additional 118,994 shares during the last quarter. Finally, General Atlantic L.P. increased its position in Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.